Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Metablomics for FAH edited HCC cell lines

ABSTRACT: FAH knockdown SNU-182 cells and corresponding controls were used for metabolic flux analysis. Parallel [U-¹³C₆]-glucose metabolic flux was conducted

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Hepatocyte

DISEASE(S): Disease Free

SUBMITTER: Tengchuang Ma

LAB HEAD: Tengchuang Ma

PROVIDER: PXD072255 | Pride | 2026-06-22

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	checksum.txt	Txt
	de.zip	Other
	metablomic.zip	Other
	metabolic-flux-results.xlsx	Xlsx
	metabolites-list.xlsx	Xlsx

Items per page:

1 - 5 of 5

Similar Datasets

Mass Spectrometry Footprinting Reveals How Kinetic Stabilizers Counteract Transthyretin Dynamics Altered by Pathogenic Mutations

Project description:Mass Spectrometry Footprinting Reveals How Kinetic Stabilizers Counteract Transthyretin Dynamics Altered by Pathogenic Mutations

2025-12-13 | PXD071902 | Pride

Role of SIRT1 in human hepatocellular carcinoma

Project description:To investigate the specific roles of SIRT1 in the development of hepatocellular carcinoma, we employed large-scale gene expression analysis to identify the molecular signature that may affect enabling characteristics of cancer cells. Differentially expressed genes were analyzed on the SNU-182 cells transfected with SIRT1 siRNA and recapitulated molecular signatures that related to hallmarks of cancer. SIRT1 expression in hepatocellular carcinoma was analyzed by RT-PCR and western blot. RNA interference-mediated protein knockdown method was used to investigate oncogenic potential of SIRT1 in hepatocelluar carcinoma

2012-03-01 | E-GEOD-32066 | biostudies-arrayexpress

Research Dataset for Immune-Related Adverse Events Affecting the Central Nervous System

Project description:This dataset contains all research data collected for irAE-CNS conducted between 2019.1 and 2024.9. The collection includes files comprising experimental measurements, survey responses, processed analyses. Data formats include CSV, RDATA, and Excel. The complete dataset is organized into categories. All files follow consistent naming conventions and include detailed metadata describing collection methods, instruments/settings used, and processing steps.

2026-02-13 | PAD000030 | Pride

Identification of p53-regulated microRNAs in Hapatocellular Carcinoma (HCC).

Project description:p53 suppresses tumor progression and metastasis by regulating a large set of genes and microRNAs. By profiling 92 primary hepatocellular carcinomas (HCCs) and 9 HCC cell lines, we found that p53 upregulates microRNAs including miR-200 and miR-192 family members. By sequencing TP53 in 92 HCC samples, we classified the 92 samples into two groups (wt and mut). We also classified 9 HCC cell lines by testing p21 expression after DNA-damage mediated p53 activation. We then profiled microRNA expression in 92 HCC tissue samples and 9 HCC celll lines to identify p53-regulated microRNAs.

2011-05-11 | E-GEOD-28661 | biostudies-arrayexpress

CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines targeting the Hippo pathway

Project description:The effects of CG200745 on SNU-1196 and SNU-1196/GR (gemcitabine resistant cell line) were assessed by cDNA and miRNA microarray analyses after 24 h of treatment.

2018-08-31 | E-MTAB-5733 | biostudies-arrayexpress

Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

Project description:miR-182 promoter hypermethylation frequently occurs in various tumors, including acute myeloid leukemia, and leads to low expression of miR-182. However, whether adult acute lymphocyte leukemia (ALL) cells have high miR-182 promoter methylation has not been determined. miR-182 (miR-182-5P) expression was substantially lower in ALL blasts than in normal controls (NCs) because of DNA hypermethylation at the miR-182 promoter in ALL blasts but not in normal controls (NCs). Knockout of miR-182 (182KO) markedly accelerated ALL development, facilitated the infiltration, and shortened the overall survival in a BCR-ABL (P190)-induced murine B-ALL model. Furthermore, the 182KO ALL cell population was enriched with more leukemia-initiating cells (CD43+B220+ cells, LICs) and presented higher leukemogenic activity than the 182WT ALL population. Furthermore, depletion of miR-182 reduced the overall survival in a Notch-induced murine T-ALL model, suggesting that miR-182 knockout accelerates ALL development. Mechanistically, overexpression of miR-182 inhibited proliferation and induced apoptosis by directly targeting PBX3 and BCL2, two well-known oncogenes that are key targets of miR-182. Most importantly, DAC in combination with Ven had synergistic effects on ALL cells with miR-182 promoter hypermethylation, but not on ALL cells with miR-182 promoter hypomethylation. Collectively, we identified miR-182 as a tumor suppressor gene in ALL cells and low expression of miR-182 because of hypermethylation facilitates the malignant phenotype of ALL cells. DAC+Ven cotreatment might has been applied in the clinical try for ALL patients with miR-182 promoter hypermethylation. The frequency of methylation at the miR-182 promoter should be a potential biomarker for DAC+Ven treatment in ALL patients.

2025-03-01 | GSE260974 | GEO

Human hepatocarcinoma cells : Huh-7 vs. SNU-739

Project description:Transcriptional profiling of human hepatocarcinoma comparing Huh-7 and SNU-739. Two-condition experiment, normalized ratio represented by Huh-7/SNU-739. Biological replicates: 2 Huh-7 replicates, 2 SNU-739 replicates.

2014-04-29 | E-GEOD-57106 | biostudies-arrayexpress

SCAMP3-Driven Regulation of ERK1/2 and Autophagy Phosphoproteomics Signatures in Triple-Negative Breast Cancer

Project description:Despite the promise of ERK1/2 pathway inhibitors, their efficacy is often limited by feedback mechanisms and pathway adaptability, emphasizing the need to identify co-regulatory proteins that modulate ERK1/2 signaling. Previously, we identified secretory carrier membrane protein 3 (SCAMP3) as a key driver of TNBC progression and a regulator of ERK1/2 activation. In this study, we investigated the role of SCAMP3 in ERK1/2 signaling networks using Tandem Mass Tag (TMT) LC-MS/MS-based phosphoproteomics in TNBC SUM-149 cells and SCAMP3 knockout models treated with the ERK1/2 inhibitor MK-8353. We identified 4,431 phosphosites and detected alterations in nuclear ERK1/2 substrates (ELF1, ELF4), cytoplasmic feedback regulators (Raf-1, MEK2), metabolic enzymes (PCYT1A), and autophagy-related proteins (OPTN, SQSTM1/p62, and TBC1D5), following SCAMP3 knockout. Western blot analysis of SQSTM1/p62, OPTN, and LC3B validated that ERK inhibition was associated with increased SQSTM1/p62 and LC3B-II levels, implicating impaired autophagy flux. Furthermore, silencing of SCAMP3 also affected phosphorylation events mediated by AKT, mTOR, CDK2, CK2, and PKA. Taken together, our findings position SCAMP3 as a central regulator of ERK1/2 signaling and support its potential as a therapeutic target alone or in combination with ERK1/2 inhibitors for TNBC patients.

2025-10-27 | PXD064784 | Pride

Single-cell DNA sequencing analysis of ecDNA copy-number dynamics during drug adaptation

Project description:Single-cell DNA sequencing was performed using the Mission Bio Tapestri platform to analyze ecDNA-associated copy-number dynamics across cancer cell lines, single-cell-derived clones, and drug-treated conditions. Droplet-based targeted PCR amplification was carried out according to the manufacturer’s instructions using custom primer panels designed to quantify ecDNA-associated loci, control genomic regions, and barcode sequences. The dataset includes parental cancer cell lines, including COLO320DM, COLO320HSR, H2170, SNU-16, PC-3, and RPE1 control cells, as well as multiple COLO320DM-derived single-cell clones. Selected clones were analyzed under basal conditions and after drug treatment, including DMSO and JQ1. Sequencing libraries were prepared following the manufacturer’s protocol and sequenced using the Illumina NextSeq 550 platform with 2 × 75 bp paired-end reads.

2026-05-25 | E-MTAB-16119 | biostudies-arrayexpress

Human holo-transferrin glycation

Project description:Understanding the effect of glycation on the function of transferrin, the systemic iron transporter, is fundamental to fully grasp the mechanisms leading to the loss of iron homeostasis observed in diabetes mellitus (DM). The spontaneous reaction with protein amino groups is one of the main causes of glucose toxicity, but the site specificity of this reaction is still poorly understood. Unbalance of iron metabolism has long been described in DM patients, and one of the main features is the occurrence of non-transferrin-bound iron in the blood serum. The presence of these toxic iron species is observed, despite low transferrin saturation levels. Here in, an in vitro approach was used to study human holo-transferrin glycation in detail. Holo-transferrin was incubated with increasing concentration of glucose (10; 20; 100 and 500 mM) and glycation sites were identified using nano-reverse phase – liquid chromatography coupled to high resolution mass spectrometry (nLC-MS). Overall 21 glycation hotspots were identified with lysine residues 103, 312 and 380 proving to be the most reactive sites. Glycation specificity was found to be remarkably different from that described for apo-transferrin.

2018-05-30 | PXD009345 | Pride